Potential use of 10-year and lifetime coronary risk information for preventive cardiology prescribing decisions: A primary care physician survey

Archives of Internal Medicine

Volumn 170, Issue 5, 2010, Pages 470-477

  Persell, Stephen D ^a   Zei, Charles ^a   Cameron, Kenzie A ^a   Zielinski, Michael ^a   Lloyd Jones, Donald M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; FIBRINOLYTIC AGENT; LIPID;

ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL DECISION MAKING; CONTROLLED STUDY; GENERAL PRACTITIONER; HEALTH SURVEY; HEART DEATH; HEART INFARCTION; INFORMATION DISSEMINATION; LOW DRUG DOSE; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK MANAGEMENT; ADULT; BLOOD; CARDIOLOGY; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; DECISION SUPPORT SYSTEM; FEMALE; GENERAL PRACTICE; HEALTH CARE SURVEY; HUMAN; INTERNAL MEDICINE; MALE; METHODOLOGY; MIDDLE AGED; QUESTIONNAIRE; RISK FACTOR; STANDARD; STATISTICS;

ADULT; ANTICHOLESTEREMIC AGENTS; ASPIRIN; CARDIOLOGY; CORONARY DISEASE; DECISION SUPPORT TECHNIQUES; DRUG PRESCRIPTIONS; FAMILY PRACTICE; FEMALE; FIBRINOLYTIC AGENTS; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HUMANS; INTERNAL MEDICINE; LIPIDS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS, FAMILY; PRACTICE GUIDELINES AS TOPIC; PRESCRIPTIONS; PRIMARY PREVENTION; QUESTIONNAIRES; RISK FACTORS;

EID: 77950359289     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2009.525     Document Type: Article

References (33)

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25): 3143-3421.
2. Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases: American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002;106(3):388-391.
3. Mosca L, Appel LJ, Benjamin EJ, et al; American Heart Association. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation. 2004;109(5):672-693. (Pubitemid 38326128)
4. Grundy SM, Cleeman JI, Merz CN, et al; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227-239.
5. US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150(6):396-404.
6. Mosca L, Linfante AH, Benjamin EJ, et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation. 2005; 111(4):499-510. (Pubitemid 40204436)
7. Framingham Heart Study. http://www.framinghamheartstudy.org/risk/ hrdcoronary .html. Accessed February 18, 2009.
8. Conroy RM, Pyorala K, Fitzgerald AP, et al; SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987-1003.
9. Sheridan S, Pignone M, Mulrow C. Framingham-based tools to calculate the global risk of coronary heart disease: a systematic review of tools for clinicians. J Gen Intern Med. 2003;18(12):1039-1052.
10. van Wyk JT, van Wijk MA, Sturkenboom MC, Mosseveld M, Moorman PW, van der Lei J. Electronic alerts versus on-demand decision support to improve dyslipidemia treatment: a cluster randomized controlled trial. Circulation. 2008; 117(3):371-378.
11. Hall LM, Jung RT, Leese GP. Controlled trial of effect of documented cardiovascular risk scores on prescribing. BMJ. 2003;326(7383):251-252.
12. Engberg M, Christensen B, Karlsmose B, Lous J, Lauritzen T. General health screenings to improve cardiovascular risk profiles: a randomized controlled trial in general practice with 5-year follow-up. J Fam Pract. 2002;51(6):546-552. (Pubitemid 34602990)
13. Grover SA, Lowensteyn I, Joseph L, et al; Cardiovascular Health Evaluation to Improve Compliance and Knowledge Among Uninformed Patients (CHECK-UP) Study Group. Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy: the CHECK-UP study: a randomized controlled trial. Arch Intern Med. 2007;167(21):2296-2303.
14. Sheridan SL, Crespo E. Does the routine use of global coronary heart disease risk scores translate into clinical benefits or harms? a systematic review of the literature. BMC Health Serv Res. 2008;8:60.
15. Montgomery AA, Fahey T, Peters TJ, MacIntosh C, Sharp DJ. Evaluation of computer based clinical decision support system and risk chart for management of hypertension in primary care: randomised controlled trial. BMJ. 2000;320(7236): 686-690.
16. Pignone M, Anderson GK, Binns K, Tilson HH, Weisman SM. Aspirin use among adults aged 40 and older in the United States: results of a national survey. Am J Prev Med. 2007;32(5):403-407.
17. Stafford RS, Monti V, Ma J. Underutilization of aspirin persists in US ambulatory care for the secondary and primary prevention of cardiovascular disease. PLoS Med. 2005;2(12):e353.
18. Manes C, Giacci L, Sciartilli A, D'Alleva A, De Caterina R. Aspirin overprescription in primary cardiovascular prevention. Thromb Res. 2006;118(4):471-477.
19. Jacobson TA, Gutkin SW, Harper CR. Effects of a global risk educational tool on primary coronary prevention: the Atherosclerosis Assessment Via Total Risk (AVIATOR) study. Curr Med Res Opin. 2006;22(6):1065-1073.
20. van Steenkiste B, van der Weijden T, Stoffers HE, Kester AD, Timmermans DR, Grol R. Improving cardiovascular risk management: a randomized, controlled trial on the effect of a decision support tool for patients and physicians. Eur J Cardiovasc Prev Rehabil. 2007;14(1):44-50.
21. Lloyd-Jones DM, Dyer AR, Wang R, Daviglus ML, Greenland P. Risk factor burden in middle age and lifetime risks for cardiovascular and non-cardiovascular death (Chicago Heart Association Detection Project in Industry). Am J Cardiol. 2007;99(4):535-540.
22. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006; 113(6):791-798.
23. Bowker AH. A test for symmetry in contingency tables. J Am Stat Assoc. 1948; 43(244):572-574.
24. Smith MA, Cox ED, Bartell JM. Overprescribing of lipid lowering agents. Qual Saf Health Care. 2006;15(4):251-257.
25. Yarzebski J, Bujor CF, Goldberg RJ, Spencer F, Lessard D, Gore JMA. A community-wide survey of physician practices and attitudes toward cholesterol management in patients with recent acute myocardial infarction. Arch Intern Med. 2002; 162(7):797-804.
26. Oliveria SA, Lapuerta P, McCarthy BD, L'Italien GJ, Berlowitz DR, Asch SM. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med. 2002;162(4):413-420. (Pubitemid 34150642)
27. Schulman KA, Mehta SS, Gersh BJ, Schneider EC, Wilcox CS. Study of Hypertensive Prescribing Practices (SHyPP): a national survey of primary care physicians. J Clin Hypertens (Greenwich). 1999;1(2):106-114.
28. Schulman KA, Berlin JA, Harless W, et al. The effect of race and sex on physicians' recommendations for cardiac catheterization. N Engl J Med. 1999;340 (8):618-626. (Pubitemid 29093722)
29. Risk assessment tool for estimating 10-year risk of developing hard CHD (myocardial infarction and coronary death). National Cholesterol Education Program Web site. http://hp2010.nhlbihin.net/atpiii/calculator.asp?usertype= prof. Accessed February 25, 2009.
30. Berry JD, Liu K, Folsom AR, et al. Prevalence and progression of subclinical atherosclerosis in younger adults with low short-term but high lifetime estimated risk for cardiovascular disease: the coronary artery risk development in young adults study and multi-ethnic study of atherosclerosis. Circulation. 2009;119 (3):382-389.
31. Baigent C, Keech A, Kearney PM, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-1278.
32. Van Wyk JT, Van Wijk MA. Assessment of the possibility to classify patients according to cholesterol guideline screening criteria using routinely recorded electronic patient record data. Stud Health Technol Inform. 2002;93:39-46.
33. Persell SD, Dunne AP, Lloyd-Jones DM, Baker DW. Electronic health record-based cardiac risk assessment and identification of unmet preventive needs. Med Care. 2009;47(4):418-424.